Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate

Immunotherapy

Volumn 4, Issue 5, 2012, Pages 549-554

  Rizvi, S M A ^a   Allen, B J ^a   Lee, C S ^a   Bruchertseifer, F ^b   Apostolidis, C ^b   Morgenstern, A ^b   Clarke, R A ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

bevacizumab 213; bismuth; PC3 xenografts; prostate cancer; targeted radioimmunotherapy

Indexed keywords

ACTINIUM 225; BEVACIZUMAB; BEVACIZUMAB BI 213; BISMUTH 213; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CHELATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; HALF LIFE TIME; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; TARGETED ALPHA RADIOIMMUNOTHERAPY; TOXICITY TESTING; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861717772     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.42     Document Type: Article

References (25)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27-31 (1995).
2. Ortholan C, Durivault J, Hannoun-Levi JM et al. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. Eur. J. Cancer 46(16), 3022-3036 (2010).
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5(12), 1359-1364 (1999).
4. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61(14), 5407-5414 (2001).
5. BokRA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res. 61(6), 2533-2536 (2001).
6. George DJ, Halabi S, Shepard TFet al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 7(7), 1932-1936 (2001).
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
8. Francini F, Pascucci A, Francini Eet al. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer 2011, 258689 (2011).
9. Ramaswamy B, Elias AD, KelbickNT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12(10), 3124-3129 (2006).
10. Allen BJ, Singla AA, Rizvi SMA et al. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 3(9), 1041-1050 (2011).
11. Allen BJ Can alpha-radioimmunotherapy increase efficacy for the systemic control of cancer? Immunotherapy 3(4), 455-458 (2011).
12. Rizvi SMA, Song EY, Raja C et al. Preparation and testing of bevacizumab radioimmunoconjugates with bismuth 213 and bismuth-205/bismuth-206. Cancer Biol. Ther. 7(10), 1547-1554 (2008).
13. Li Y, Song E, Rizvi SMA et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi labeled multiple targeted alpha radioimmunoconjugates. Clin. Cancer Res. 15(3), 865-875 (2009).
14. Wild D, Frischknecht M, Zhang H et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 71(3), 1009-1018 (2011).
15. Ranson M, Tian Z, Allen BJ, Andronicos NM, Rizvi SMA. In vitro cytotoxicity of bismuth 213 )-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells. Breast Cancer Res. Treat. 71(2), 149-159 (2002).
16. Qu CF, Song EY, Li Y et al. Preclinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin. Exp. Metastasis 22, 575-586 (2005).
17. Li, Y, Rizvi SMA, Ranson M, Allen BJ. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J. Cancer 86(7), 1197-1203 (2002).
18. Song YJ, Qu CF, Rizvi SMA et al. Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope bismuth 213 for ovarian cancer cell monolayers and clusters. Cancer Lett. 234(2), 176-183 (2006).
19. Allen BJ, Tian Z, Rizvi SMA, Li Y, Ranson M. Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Br J. Cancer 88(6), 944-950 (2003).
20. Rizvi SMA, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res. 10, 281-289 (2000).
21. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res. 57(8), 1584-1589 (1997).
22. Allen BJ. Future prospects for targeted alpha therapy. Curr. Radiopharm. 4(4), 336-342 (2011).
23. Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. doi:10.1200/JCO.2011.39.4767 (2012) (Epub ahead of print)
24. Ross RW, Galsky MD, Febbo P et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risklocalized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial. Cancer doi:10.1002/cncr.27416. (2012) (Epub ahead of print).
25. Vuky J, Pham HT, Warren S et al. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-riskprostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82(4), e609-e615 (2012).